- Report
- October 2025
- 98 Pages
Singapore
From €4037EUR$4,500USD£3,451GBP
- Report
- September 2025
- 97 Pages
Italy
From €4037EUR$4,500USD£3,451GBP
- Report
- September 2025
- 88 Pages
United Kingdom
From €4037EUR$4,500USD£3,451GBP
- Report
- June 2025
- 90 Pages
Global
From €4037EUR$4,500USD£3,451GBP
- Training
- April 2025
- 1 Day
Global
From €770EUR$859USD£658GBP
- Report
- December 2024
- 96 Pages
Global
From €3999EUR$4,775USD£3,538GBP
- Report
- January 2024
- 48 Pages
India
- Report
- August 2023
- 172 Pages
Global
From €4171EUR$4,650USD£3,566GBP
- Database
- July 2023
Global
From €323EUR$360USD£276GBP
- Report
- June 2023
Global
From €1346EUR$1,500USD£1,150GBP
- Report
- June 2022
- 55 Pages
Global
From €4440EUR$4,950USD£3,796GBP
- Report
- April 2022
Global
€8971EUR$10,000USD£7,669GBP
- Report
- September 2018
- 15 Pages
Global
- Report
- October 2022
- 307 Pages
Global
From €2243EUR$2,500USD£1,917GBP
- Report
- May 2023
- 80 Pages
Russia
From €1346EUR$1,500USD£1,150GBP
- Report
- January 2024
- 124 Pages
Global
From €3500EUR$4,180USD£3,097GBP
- Report
- January 2025
- 132 Pages
Global
From €852EUR$950USD£729GBP
The Drug Discovery AI market is a rapidly growing sector of the pharmaceutical industry, focused on the development of artificial intelligence (AI) technologies to aid in the discovery of new drugs. AI-driven drug discovery is a process that uses machine learning algorithms to identify potential drug targets and develop new drug candidates. AI-driven drug discovery can reduce the time and cost of drug development, as well as improve the accuracy of drug discovery.
The Drug Discovery AI market is composed of a variety of companies, ranging from large pharmaceutical companies to small startups. Companies in the market include Atomwise, Exscientia, Insilico Medicine, and Recursion Pharmaceuticals. These companies are developing AI-driven drug discovery technologies to help accelerate the drug discovery process. Show Less Read more
